SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.810.0%Nov 24 3:58 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote (4208)10/21/1997 3:09:00 PM
From: opalapril  Read Replies (2) of 17367
 
Sad to say, but I am afraid the odds favor only a modest rise in XOMA's stock price if the results are positive and then another drift down to the usual crippled trading range. Other biotechs -- lesser ones, I might add --see a big, permament stock price increase in a short time after a single clinical success. But in XOMa's case, because of its checkered (i.e. "frustrating") past, merely confirming what is already known will not excite Wall Street or the funds that drive the market. Ultimately, the only thing that will convince them and send XOMA soaring is a lucrative long-term manufacturing and marketing agreement with a mega-pharmaceutical company for a specific BPI-derived drug -- in other words, positive proof that XOMA exists to make money, not just provide a test tube playground for woolly headed scientists. What would send the stock reeling, of course, are disappointing clinical results -- which the whole investment world thinks is unlikely to happen.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext